CoChat

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease

Open access
Mann, Johannes F.E., Fonseca, Vivian A., Poulter, Neil R., Raz, Itamar, Idorn, Thomas, Rasmussen, Søren, von Scholten, Bernt Johan, Mosenzon, Ofri, on behalf of the LEADER Trial Investigators · 2020 · Clinical Journal of the American Society of Nephrology

Abstract

Background and objectives: The glucagon-like peptide-1 receptor agonist liraglutide demonstrated cardiovascular and kidney benefits in the LEADER trial, particularly in participants with CKD. Design, setting, participants, & measurements: This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER. Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care. Of those, 2158 patients had CKD versus 7182 without CKD (defined as eGFR <60 versus ≥60 ml/min per 1.73 m 2 , respectively); 966 patients had macroalbuminuria and 2456 had microalbuminuria (urine albumin-creatinine ratio >300 mg/g and ≥30 to ≤300 mg/g, respectively). At baseline, the mean eGFR in patients with CKD was 46±11 ml/min per 1.73 m 2 versus 91±22 ml/min per 1.73 m 2 in those without CKD. Time to first event within event groups was analyzed using Cox regression with treatment group, baseline eGFR group, or baseline albuminuria group as fixed factors. Results: Overall, serious adverse events were more frequently recorded in patients with CKD compared with those without CKD (59% versus 50%; interaction P =0.11); however, they occurred to the same extent in those on liraglutide versus placebo. Similarly, no interaction of adverse events with randomized therapy was observed in patients with micro- or macro- versus normoalbuminuria (interaction P =0.11). Risk of severe hypoglycemia was significantly reduced with liraglutide versus placebo in patients with CKD or with micro- or macroalbuminuria (hazard ratio, 0.63 [95% CI, 0.43 to 0.91] and 0.57 [95% CI, 0.40 to 0.82], respectively). Conclusions: In LEADER, the use of liraglutide in those with CKD was safe, with no difference between patients with and without CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov; NCT01179048 (https://clinicaltrials.gov/ct2/show/NCT01179048).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.11881019

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 50

Metadata

Authors
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators
Affiliations
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Tulane University (US)
  • Imperial College London (GB)
  • Hadassah Medical Center (IL)
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk A/S, Søborg, Denmark
Corresponding author
Mann, Johannes F.E.
Venue
Clinical Journal of the American Society of Nephrology
Published
2020-03-04
Volume
15
Issue
4
Pages
465-473
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W3010392113
Cited by
50
References
39
Citations by year
2026: 5 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 8 · 2021: 12 · 2020: 5
FWCI
6.22
Type
journal article
Language
en
Open access
Locations
  • Clinical Journal of the American Society of Nephrology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
liraglutide, type 2 diabetes, chronic kidney disease, GLP-1 receptor agonists, drug safety, LEADER trial, albuminuria, microalbuminuria, macroalbuminuria, hypoglycemia, serious adverse events, EGFR, cardiovascular outcomes, renal outcomes, drug interactions
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Kidney, Male, Middle Aged, Time Factors, Biomarkers, Treatment Outcome, Renal Insufficiency, Chronic, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. https://app.cochat.ai/papers/10.2215/cjn.11881019
The paper
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators. (2020). Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.11881019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.